Treatment for Specific Phobias in Children

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Thomas H. Ollendick, Virginia Polytechnic Institute and State University
ClinicalTrials.gov Identifier:
NCT00051220
First received: January 7, 2003
Last updated: June 6, 2013
Last verified: June 2013
  Purpose

This study will compare the effectiveness of three treatments in reducing symptoms of phobia in children and adolescents.


Condition Intervention Phase
Phobic Disorders
Anxiety Disorders
Behavioral: One-Session Treatment for Specific Phobias
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: One-Session Treatment for Specific Phobias in Children

Resource links provided by NLM:


Further study details as provided by Virginia Polytechnic Institute and State University:

Enrollment: 150
Study Start Date: October 2001
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Children with specific phobias may experience academic, social, and personal distress, as well as interference in day-to-day activities. One-Session Treatment has been found a rapid and effective treatment for adults with phobic disorders. However, its utility in the treatment of childhood phobia has not been examined.

Participants are randomly assigned to 1 of 3 groups: a one-session treatment group, an education/support group, and a waitlist control group. The one-session treatment group is directly exposed to a phobia object or situation during a 3-hour treatment session. In the education/support group, children are given information about fear and phobias and are taught how to deal with them through workbook activities. Children who participate in the one-session treatment group or the education/support group are assessed 1 week post-treatment and again after 6 months. Participants with improved symptoms have a 1-year follow-up. Participants with phobias that persist at 6 months are encouraged to participate in alternative treatment. Waitlist control participants are assessed pre-treatment and 1 month post-treatment. Those who continue to have phobias at the 1-month assessment are randomly assigned to 1 of the 2 active treatments.

  Eligibility

Ages Eligible for Study:   7 Years to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Primary diagnosis of specific phobia disorder

Exclusion Criteria:

  • Mental retardation
  • Developmental disabilities
  • Suicide threat
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051220

Locations
United States, Virginia
VA Polytech. Institute and State University
Blacksburg, Virginia, United States
Sweden
University of Stockholm
Stockholm, Sweden
Sponsors and Collaborators
Virginia Polytechnic Institute and State University
  More Information

No publications provided

Responsible Party: Thomas H. Ollendick, Professor, Virginia Polytechnic Institute and State University
ClinicalTrials.gov Identifier: NCT00051220     History of Changes
Other Study ID Numbers: R01 MH59308, R01MH059308, DSIR CT-S
Study First Received: January 7, 2003
Last Updated: June 6, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Disease
Anxiety Disorders
Phobic Disorders
Pathologic Processes
Mental Disorders

ClinicalTrials.gov processed this record on September 29, 2014